MRI of the 'Alzheimer syndrome'

M C Henry-Feugeas1

  • 1Department of Radiology, Bichat-Claude-Bernard University Hospital, APHP, 46, rue Henri-Huchard, 75877 Paris cedex 18, France. marie-cecile.henry-feugeas@bch.ap-hop-paris.fr

Insights

Magnetic resonance imaging (MRI) can detect early Alzheimer's disease (AD) changes, but differentiating AD from vascular cognitive impairment is challenging. MRI findings may overestimate AD pathology and underestimate vascular disease in

Area of Science:

  • Neuroimaging
  • Neurology
  • Radiology

Background:

  • Growing interest in early cognitive decline and Alzheimer's disease (AD) heterogeneity fuels neuroimaging research.
  • Magnetic resonance imaging (MRI) detects early atrophic changes in AD, preceding clinical symptoms.
  • Cerebrovascular disease can mimic AD, presenting similar imaging markers.

Purpose of the Study:

  • To investigate the utility of MRI in differentiating early Alzheimer's disease (AD) from vascular cognitive impairment.
  • To analyze MRI patterns in prodromal forms of late-onset dementia of Alzheimer's type (DAT).
  • To assess the accuracy of current MRI measurements in distinguishing AD-specific atrophy from other forms of brain degeneration.

Main Methods:

  • Review of neuroimaging studies focusing on Alzheimer's disease (AD) and cerebrovascular disease.
  • Analysis of MRI markers, including atrophy patterns (mesiotemporal, hippocampal) and signs of subcortical vascular disease.
  • Differentiation of imaging patterns in amnesic single-domain mild cognitive impairment and other predementia states.

Main Results:

  • MRI can detect early brain atrophy suggestive of Alzheimer's disease (AD) years before symptom onset.
  • Subcortical vascular disease markers on MRI are associated with vascular-related cognitive impairment.
  • Current MRI methods struggle to differentiate AD-specific anteromesial temporal atrophy from hippocampal atrophy linked to vascular disease.

Conclusions:

  • MRI findings in late-onset dementia may overestimate Alzheimer's disease (AD) pathology.
  • MRI may underestimate 'arteriosclerotic brain degeneration' in cases clinically presenting as 'Alzheimer syndrome'.
  • Refined MRI analysis is needed to accurately distinguish AD from vascular contributions to cognitive decline.

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...